Lv1
60 积分 2021-12-03 加入
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
14天前
已完结
MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies
2个月前
已关闭
Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients
2个月前
已关闭
Fundamental aspects of DMPK optimization of targeted protein degraders
4个月前
已完结
Opinion on Qualitative Severity Descriptors to Express Magnitude of Changes in Clinical Pathology Endpoints in Nonclinical Toxicity Studies
4个月前
已完结
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
5个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
5个月前
已完结
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
5个月前
已完结
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
5个月前
已完结
Targeted protein degraders: a call for collective action to advance safety assessment
5个月前
已完结
皖公网安备34019202002308
